Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LEAP THERAPEUTICS, INC. (LPTX)
|
Add to portfolio |
|
|
|
| Price: |
$1.73
| | Metrics |
| OS: |
25.6
|
M
| |
-98
|
% ROE
|
| Market cap: |
$44.2
|
M
| |
|
|
|
Net cash:
|
$91.4
|
M
| |
$3.58
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($86.6)
|
M
| |
|
|
|
EBIT
|
($86.6)
|
M
| |
|
|
| EPS |
($1.47)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 1.5 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 10.4 |
| Revenue growth | -100.0% | 0.0% | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.4 |
| Gross profit | 0.0 | 1.5 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | 100.0% | | | | | 0.0% |
| Research and development | 45.0 | 32.2 | 20.4 | 24.4 | 21.8 | 22.5 | 23.3 | |
| General and administrative | 11.8 | 10.8 | 9.6 | 9.1 | 8.9 | 9.8 | 4.0 | 1.5 |
| EBIT | -56.8 | -41.4 | -28.5 | -33.5 | -30.8 | -32.4 | -27.3 | -11.9 |
| EBIT margin | | -2761.7% | -1902.6% | | | | | -114.5% |
| Pre-tax income | -54.4 | -40.6 | -27.5 | -32.9 | -23.1 | -29.9 | -25.6 | -12.1 |
| Income taxes | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | 0.0 |
| Tax rate | | 0.1% | 0.0% | 0.0% | | 0.5% | 0.0% | 0.0% |
| Net income | -54.6 | -40.6 | -37.6 | -33.3 | -23.1 | -30.0 | -25.6 | -12.1 |
| Net margin | | -2705.8% | -2505.9% | | | | | -115.7% |
| |
| Diluted EPS | ($0.48) | ($0.47) | ($0.63) | ($1.47) | ($1.61) | ($3.26) | | |
| Shares outstanding (diluted) | 113.2 | 85.8 | 59.3 | 22.6 | 14.4 | 9.2 | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|